News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
News Vertex seeks deal after NICE rejects CF drug Orkambi Company in talks with NICE over patient access scheme.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.